Research programme: anticancer protein therapeutics - CuraGen

Drug Profile

Research programme: anticancer protein therapeutics - CuraGen

Alternative Names: Anticancer protein therapeutics research programme - CuraGen; CG 51896; CG 53449; CG 55069; CG 55069-11; CG 57067

Latest Information Update: 27 Aug 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CuraGen Corporation
  • Class Proteins
  • Mechanism of Action Angiogenesis inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 06 Apr 2004 Data presented at the 95th Annual Meeting of the American Association for Cancer Research (AACR-2004) have been added to the Cancer pharmacodynamics section ,
  • 20 Aug 2003 This programme is still in active development
  • 17 Apr 2002 Preclinical trials in Solid tumours in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top